CTLA4 and oral cavity squamous cell carcinoma: In a phase II trial (NCT03799445), the combination therapy of anti‐PD‐1 and anti‐CTLA‐4 antibodies with RT is being investigated for patients with HPV‐positive oral squamous cell carcinoma.